Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Veracyte

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes

The Guardian - UK · May 29

Cathie Wood Offloads Millions of Biotech Shares, Ramps Stake in Veracyte Days Before Earnings Beat

Cathie Wood's Ark Invest sold shares of five biotech and healthcare companies in recent trades. She also offloaded over 1.1 million shares of streaming tech firm Roku.

International Business Times UK · Nov 5, 2025

Is Cathie Wood Cashing Out? Ark CEO Dumps Millions in Biopharma and Aviation Stocks

Cathie Wood aggressively sold shares of Adaptive Biotechnologies, Veracyte, and Archer Aviation on 31st May, according to a 6th June filing with the SEC.

International Business Times UK · Jun 9, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Navigating 9 Analyst Ratings For Veracyte

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga · Dec 5, 2024

Is Veracyte a Smart Bet in Genomic Diagnostics?

Veracyte (VCYT) exceeded Wall Street’s expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out….

StockNews.com · Jul 5, 2024

Veracyte Earnings Perspective: Return On Capital Employed

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.

Benzinga · May 13, 2022

Analyst Ratings for Veracyte

Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:

Benzinga · May 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Veracyte Q1 Earnings

Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 16.67%, reporting an EPS of $-0.2 versus an estimate of $-0.24.

Benzinga · May 3, 2022

Preview: Veracyte's Earnings

Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will report an earnings per share (EPS) of $-0.24.

Benzinga · May 2, 2022

Veracyte's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Veracyte (NASDAQ:VCYT) posted sales of $67.34 million. Earnings were up 25.49%, but Veracyte still reported an overall loss of $10.53 million.

Benzinga · Mar 2, 2022

Recap: Veracyte Q4 Earnings

Veracyte (NASDAQ:VCYT) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 6.25%, reporting an EPS of $-0.15 versus an estimate of $-0.16.

Benzinga · Feb 28, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Adaptive Biotechnologies

12 stories

Veracyte

11 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.